Gilead Sciences has secured another synthetic lethal therapy, handing $80 million upfront for the global rights to a...
Gilead paid $80 million upfront for global rights to Genhouse Bio's clinic-ready synthetic‑lethal cancer drug from China, expanding its oncology portfolio.
Why it mattersGilead's $80 million deal for Genhouse Bio's clinic-ready synthetic-lethal cancer drug raises licensing valuation expectations for oncology assets.